Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)

  • Keisuke Izumi,
  • Yuko Kaneko,
  • Misato Hashizume,
  • Keiko Yoshimoto,
  • Tsutomu Takeuchi

The x-axis in Panel A within S5 Fig is labeled incorrectly. It should read: 10, 20, 30, 40. Please view the correct S5 Fig below.

Supporting Information

S5 Fig. Predictive ability of OPN for CDAI remission in patients with RA who received TCZ with concomitant MTX.

https://doi.org/10.1371/journal.pone.0152341.s001

(TIF)

Reference

  1. 1. Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T (2015) Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLoS ONE 10(12): e0145468. pmid:26698858

Citation: Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T (2016) Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLoS ONE 11(3): e0152341. https://doi.org/10.1371/journal.pone.0152341

Published: March 21, 2016

Copyright: © 2016 Izumi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.